Key result
Non-use of serum or plasma in BMC suspension and avoiding heparin without cell washout were associated with greater reduction in infarct size and lower all-cause mortality in AMI patients.
Why the study?
Do methodological differences in bone marrow-derived stem cell preparation affect cardiac outcomes and mortality in patients with acute myocardial infarction?
Meta-Analysis
Do methodological differences in bone marrow-derived stem cell preparation affect cardiac outcomes and mortality in patients with acute myocardial infarction?
Methodological differences in bone marrow stem cell preparation, specifically avoiding serum/plasma and heparin, may improve infarct size reduction and mortality outcomes in AMI patients.
May guide BMC preparation in future AMI trials; extends meta-analyses by identifying key methodological factors.
BACKGROUND: Clinical trials of intracoronary injection of bone marrow-derived stem cells (BMCs) in patients with acute myocardial infarction (AMI) have revealed promising but variable and modest results. One of the reasons underlying this situation may be the unstandardized preparation of BMCs. OBJECTIVES: The aim of this study was to explore whether methodological differences affect the prognosis of acute myocardial infarction patients who received BMCs transplantation. MATERIAL AND METHODS: MEDLINE was searched for randomized controlled trials providing AMI patients with intracoronary BMCs injection or a standard therapy. Changes in cardiac parameters and clinical outcomes were analyzed. Subgroup analyses were conducted according to different methodologies for cell preparation, including supplement for serum or plasma, use of heparin and cell washout. RESULTS: Non-use of serum or plasma in the cell suspension is associated with more reduction in infarct size (IS) and a lower risk of all-cause mortality. Heparin usage could diminish the benefit in reducing IS. All-cause mortality rose significantly without the cell washout procedure when heparin was used. CONCLUSIONS: Methodological differences in BMCs preparation as well as the use of heparin and serum/ plasma impact on the prognosis of AMI patients.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2018) conducted a meta-analysis in acute myocardial infarction. Intracoronary injection of bone marrow-derived stem cells (BMCs) vs. Standard therapy was evaluated on Changes in cardiac parameters and clinical outcomes. Non-use of serum or plasma in BMC suspension and avoiding heparin without cell washout were associated with greater reduction in infarct size and lower all-cause mortality in AMI patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: